Pharmacodynamic Equivalence Study of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular Fixed Dose Combination Pill AAR as Compared to Monotherapy With the Reference Products Altace 10 mg and Lipitor 40 mg

Trial Profile

Pharmacodynamic Equivalence Study of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular Fixed Dose Combination Pill AAR as Compared to Monotherapy With the Reference Products Altace 10 mg and Lipitor 40 mg

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Aspirin/atorvastatin/ramipril (Primary) ; Atorvastatin; Ramipril
  • Indications Cardiovascular disorders; Hypertension
  • Focus Therapeutic Use
  • Sponsors Ferrer
  • Most Recent Events

    • 07 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Apr 2017 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
    • 03 Apr 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top